TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25749543
Drug: Placebo-water in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-water in oil emulsion type cream applied to the left ear for 15 days
Study: 19229603
Drug: ivabradine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine therapy
Study: 18274218
Drug: Sequential-timing tasks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential-timing tasks
Study: 15807926
Drug: Endocrine agents
Normalized name: ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine agents like aromatase inhibitors and luteinizing hormone-releasing hormone agonists
Study: 8690815
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg twice daily of befloxatone
Study: 8690815
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg once daily of befloxatone
Study: 25751300
Drug: Alpha-Lipoic Acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-Lipoic Acid (ALA) 1200 mg/day for 8 weeks
Study: 20951527
Drug: Short-axis approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-axis approach to ultrasound-guided peripheral intravenous access (USGPIV)
Study: 20951527
Drug: Long-axis approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-axis approach to ultrasound-guided peripheral intravenous access (USGPIV)
Study: 17099514
Drug: 4 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL/kg 7.5% NaCl
Study: 17099514
Drug: 4 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL/kg 0.9% NaCl
Study: 17099514
Drug: 32 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mL/kg 0.9% NaCl
Study: 1407911
Drug: Expectant management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant management plus antimicrobial therapy (intravenous ampicillin, gentamicin, and clindamycin for 24 hours, followed by amoxicillin plus clavulanic acid orally for 7 days.
Study: 1407911
Drug: Expectant management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant management plus antimicrobial therapy
Study: 30253776
Drug: Strength exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength exercises embedded in physical education classes (15-30 min, 2x per week) plus monthly motivational lessons
Study: 24958355
Drug: Telehealth device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth device (electronic pill box)
Study: 24958355
Drug: Passive medication
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive medication reminder devices (silent)
Study: 16157523
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (3 monthly courses)
Study: 1802636
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (66 mg elemental iron daily)
Study: 21516496
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + Tamsulosin (TAM)
Study: 21516496
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + Placebo
Study: 12890302
Drug: Amisulpride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (100 mg b.i.d.)
Study: 8606066
Drug: 0.8 ng
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 ng of Salmonella abortus equi endotoxin per kg of body weight administered intravenously at 0900 h
Study: 25122647
Drug: Pregnant women
Normalized name: Hydroxyprogesterone Caproate 250mg/1mL Solution for injection [For Non-pregnant Women]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnant women consuming 57 μg of dietary biotin/d
Study: 25122647
Drug: Lactating women
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactating women consuming 57 μg of dietary biotin/d
Study: 10022631
Drug: Formula UBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula UBT with 270 ml of mixed formula meal (1 Kcal/ml)
Study: 10022631
Drug: L-DOPA pretreatment
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA pretreatment (500 mg given 30 min before [13C]-urea load)
Study: 2272718
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg acenocoumarol in combination with cimetidine
Study: 2272718
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg acenocoumarol in combination with placebo
Study: 2272718
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg acenocoumarol after one week pretreatment with pentobarbitone
Study: 31786651
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2400 mg
Study: 30384775
Drug: Psychoanalytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic therapy (PAT)
Study: 23879213
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone prescribed, tailored dosing regimen; measured urine concentration 10 to 14 days after starting treatment.
Study: 23879213
Drug: Model for
Normalized name: Model AA 2012 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model for predicting oxycodone in urine.
Study: 9452696
Drug: Mouthwash based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash based on Zea mays L
Study: 31152308
Drug: iv methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv methylprednisolone (20 mg b.i.d)
Study: 14709944
Drug: Atomoxetine (discontinued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (discontinued after 9 to 10 weeks of continuous therapy)
Study: 14709944
Drug: Placebo (continuing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (continuing treatment)
Study: 7934135
Drug: Baseline erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline erythropoietin level < 50 mU/ml
Study: 3207009
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics plus acute myringotomy (group B)
Study: 3207009
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (group A)
Study: 28817201
Drug: Biologics for
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics for rheumatoid arthritis
Study: 28817201
Drug: Different doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different doses of biologics
Study: 26005963
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (250 mg bid)
Study: 21418923
Drug: r‐bFGF eye-gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐bFGF eye-gel, four times a day
Study: 18482663
Drug: Low-flow-mediated constriction
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow-mediated constriction (L-FMC)
Study: 11020033
Drug: Aerosolized standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized standard heparin (1.000 U/kg)
Study: 11020033
Drug: Aerosolized LMWH
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized LMWH (Enoksaparin, Clexane, 0.8 mg/kg)
Study: 9244815
Drug: Gamma-linolenic acid
Normalized name: gamma-linolenic acid
DrugBank: Gamolenic acid (DB13854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-linolenic acid from borage seed oil (360 mg daily)
Study: 3937220
Drug: Stored plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stored plasma (250-300 ml, n = 5)
Study: 17277790
Drug: Cryotherapy during
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy during MTX administration
Study: 17277790
Drug: No cryotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cryotherapy during MTX administration (Control)
Study: 15204668
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment for co-occurring conditions
Study: 31799861
Drug: ERAS protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERAS protocol with postoperative intravenous Flubiprofen Axetil or analgesia pump
Study: 27861190
Drug: Dual acid-etched
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual acid-etched (DAE) implants
Study: 25741159
Drug: Tissue selecting
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue selecting therapy stapler (TST)
Study: 24474353
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group A (10 mL 17% EDTA and 10 mL 2.5% NaOCl)
Study: 24474353
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group C (CanalBrush and 10 mL NaOCl)
Study: 10340280
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (non-randomised arm, Control)
Study: 1959402
Drug: Isoproterenol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (5 mg)
Study: 6752874
Drug: pirprofen 800
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pirprofen 800 mg/day
Study: 6752874
Drug: ketoprofen 300
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketoprofen 300 mg/day
Study: 24022237
Drug: Active oromucosal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active oromucosal nicotine spray (1 or 2 mg)
Study: 18563517
Drug: High-dose L-alanyl-L-glutamine
Normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose L-alanyl-L-glutamine dipeptide [0.5 g/(kg day) glutamine]
Study: 18563517
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with isonitrogeneous, isocaloric, isovolemic nutritional solution
Study: 17330781
Drug: Paired samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paired samples collected before treatment and at recurrence of parasitemia.
Study: 15496604
Drug: Milk-based formula
Normalized name: Formula, Infant Oral Powder for Suspension [TUGABOOS MILK-BASED FORMULA W/IRON]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based formula with 72 mg ribonucleotides/L (FN)
Study: 9737454
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Warfarin (WAR)
Study: 2902545
Drug: Topical beta-blocker
Normalized name: Beta-HC Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beta-blocker treatment
Study: 28685397
Drug: 3QD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3QD regimen (once daily: ombitasvir/paritaprevir/ritonavir and dasabuvir)
Study: 28685397
Drug: 3‐DAA regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐DAA regimen (twice daily: ombitasvir/paritaprevir/ritonavir and dasabuvir)
Study: 17657475
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with decompression and various spondylodeses (n=13)
Study: 17657475
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (n=6)
Study: 15870625
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (21 g x d(-1))
Study: 12215281
Drug: Usual drugs
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual drugs used in the clinic for 60 days
Study: 11776765
Drug: Carboplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (100 mg, d 1-5) and 5-fluorouracil (500 mg, d 1-5) plus radiotherapy
Study: 531541
Drug: Methylprednisolone (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (daily dosage)
Study: 531541
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without therapy (Control)
Study: 24353023
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER tablets (50, 100, 150, 200, or 250 mg)
Study: 24353023
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER tablets (250 mg) administered every 12 hours (five doses)
Study: 24353023
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER tablets (250 mg) with a high-fat meal
Study: 24353023
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER tablets (single dose)
Study: 21464293
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant leptin (metreleptin) in replacement doses over 36 weeks
Study: 14702269
Drug: Continued perphenazine
Normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued perphenazine treatment
Study: 11579988
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy (E)
Study: 9360528
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) infusions at a dose of 34-46 mg HC/24 h
Study: 9360528
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) infusions
Study: 8432442
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 20 mg daily
Study: 8432442
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg daily (tapering to 10 or 20 mg)
Study: 27022118
Drug: Crizotinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (250 mg twice daily; n = 172)
Study: 27022118
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin AUC 5 to 6; n = 171)
Study: 24526744
Drug: Azithromycin 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1.5% eye drops (twice daily for 3 days)
Study: 24526744
Drug: Tobramycin 0.3%
Normalized name: TOBRAMYCIN 0.3% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 0.3% eye drops (every 2 h for 2 days, then four times daily for 5 days)
Study: 19783377
Drug: PCV chemotherapy
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCV chemotherapy plus radiation therapy (PCV + RT)
Study: 9848045
Drug: 0.5% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% silver nitrate solution
Study: 7924731
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg twice daily)
Study: 23443788
Drug: Low-intensity ultrasound
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity ultrasound treatment for 30 min daily for 3 consecutive days
Study: 23443788
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no particular treatments)
Study: 22411387
Drug: Oral powder
Normalized name: Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral powder supplement enriched with eicosapentaenoic acid (1.5 g)
Study: 22411387
Drug: Standard liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard liquid supplement
Study: 9143748
Drug: Exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise treatment (90 min/day of isotonic and isokinetic lower extremity exercise training)
Study: 27566116
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control treatment
Study: 24515352
Drug: CEPO (carbamylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEPO (carbamylated EPO) 325 µg thrice-weekly
Study: 16809804
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g P‐OM3
Study: 8964410
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group II)
Study: 8964410
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group IV)
Study: 3856903
Drug: Vaginal film
Normalized name: Vaginal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal film formulation containing 850 micrograms PGE2
Study: 26938918
Drug: SnMP (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SnMP (4.5 mg kg ‐1)
Study: 20633511
Drug: Pharmacopuncture using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacopuncture using root bark of Ulmus davidiana Planch (UDP), administered twice a week for 6 weeks
Study: 8276047
Drug: Flunitrazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1 mg) administered once daily for 8 days
Study: 8276047
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily for 8 days
Study: 28877165
Drug: Unsupervised water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised water exercise twice a week for 12 weeks
Study: 16462549
Drug: Manual-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-based treatment for schizophrenia
Study: 9291201
Drug: Candoxatrilat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatrilat (100 mg i.v. bolus)
Study: 7687206
Drug: Thyroxine (150-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine (150-200 micrograms daily for 3 months)
Study: 2942494
Drug: Flunitrazepam 2
Normalized name: flunitrazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2 mg (after three repeated doses)
Study: 27411009
Drug: Antibiotics (Vancomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (Vancomycin and Amoxicillin)
Study: 20350945
Drug: MGAWN1 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGAWN1 (0.3, 1, 3, 10, or 30 mg/kg)
Study: 20350945
Drug: MGAWN1 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGAWN1 (3 mg/kg)
Study: 20350945
Drug: MGAWN1 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGAWN1 (30 mg/kg)
Study: 18034842
Drug: Vildagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (100 mg daily, given as equally divided doses)
Study: 18034842
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg daily, given as a single q.d. dose)
Study: 11440493
Drug: Dipyridamole alone
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole alone at a dose of 75 mg t.i.d. orally for 8 weeks
Study: 7761963
Drug: Taleum (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taleum (sodium cromoglycate) inhalation aerosol
Study: 7761963
Drug: Intal powder
Normalized name: cromolyn sodium Inhalation Solution [Intal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intal powder inhaled with the aid of a spinhaler
Study: 29371479
Drug: Daratumumab in
Normalized name: daratumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab in combination with lenalidomide and dexamethasone
Study: 29371479
Drug: Daratumumab in
Normalized name: daratumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab in combination with bortezomib and dexamethasone
Study: 24243397
Drug: Multicomponent exercise
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent exercise program (4 weeks of walking, balance and cognitive exercises, followed by 4 weeks of resistance exercise performed twice weekly at 20-50% of 1RM)
Study: 20027105
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg rolofylline administered by intravenous infusion over 2 hours
Study: 15964408
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 3 g daily (n = 22)
Study: 15964408
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 2 g daily (n = 94)
Study: 15964408
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 3 g daily (n = 21)
Study: 15964408
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 2 g daily (n = 29)
Study: 11728846
Drug: Maintenance medication
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance medication
Study: 29589086
Drug: Subchondral bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subchondral bone marrow concentrate injection (average of 6500 MSCs/mL)
Study: 24630419
Drug: Alvimopan 12
Normalized name: alvimopan 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan 12 mg (maximum: 15 inpatient doses)
Study: 22906179
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care intervention with low-intensity psychological treatments delivered by IAPT services.
Study: 19889809
Drug: High (n-3)LCPUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High (n-3)LCPUFA beverage (1 g fat/kg body weight)
Study: 19889809
Drug: Low (n-3)LCPUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low (n-3)LCPUFA beverage (1 g fat/kg body weight)
Study: 16940036
Drug: Mono-protease inhibitor
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono-protease inhibitor use
Study: 16940036
Drug: Dual-protease inhibitor
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-protease inhibitor use
Study: 16319804
Drug: Maximum dose
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum dose glibenclamide (control)